Potassium Chloride
Approved · FDAAlso known as Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, BSS Ophthalmic Solution, Cena K+68 more
Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, BSS Ophthalmic Solution, Cena K, Chlorid draselny, Colyte, Dextrose 5% and Plasma-Lyte 148, Ed K+10, GaviLyte-C, GaviLyte-G, GaviLyte-N, Gavilyte-H, GoLYTELY, Ionosol-MB, Isolyte P, Isolyte S, Isolyte S and 5% Dextrose, Isolyte S in 5 % Dextrose, K-10, K-8, K-Dur, K-Dur 20, K-Norm, K-Tab, KCl, Kaliumchlorid, Kaochlor, Kaochlor S-F, Kaon-CI, Kay Ciel, Klor-Con, Klorvess, Klotrix, Medi-Lyte, Micro-K, Micro-K LS, MoviPrep, Muriate of potash, Navstel, Normosol-R, Normosol-R PH 7.4, Normosol-R and 5% Dextrose, Normosol-R in 5 % Dextrose, NuLYTELY, NuLYTELY Cherry, NuLYTELY Lemon Lime, NuLYTELY Orange, Nutrilyte, PC-10, Physiolyte, Physiosol, Plasma-Lyte, Plasma-Lyte 148, Plasmalyte A, Pokonza, ProcalAmine 3, Slow-K, Sutab, Ten-K, Thermotabs, Tis-U-Sol, TriLyte, CHLORIDE (AS POTASSIUM), Chloride of potash, Dextrose and Potassium Chloride, Dextrose/Potassium Chloride/Sodium Chloride, K-Lyte/Cl, Monopotassium chloride, POTASSIUM (AS CHLORIDE), Potassium Chloride in Sodium Chloride, Potassium Chloride-Potassium Gluconate, Potassium Chloride-Sodium Chloride.
Recent clinical, regulatory, research and industry developments relating to this drug.
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
Supplemental approval: POTASSIUM CHLORIDE (NDA206814)
Matching Perfusion and Metabolic Activity in HFpEF
Neuronal activity rapidly reprograms dendritic translation via eIF4G2:uORF binding.
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
Label change: POTASSIUM CHLORIDE (NDA206814)
Supplemental approval: POTASSIUM CHLORIDE (NDA206814)
Label change: POTASSIUM CHLORIDE (NDA206814)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- Nature neuroscience1
- Chen J1
- Darnell RB1
- Fak JJ1
- Hacisuleyman E1
- Hale CR1
- Luo JD1
- Noble N1
- Saito M1
- Bay Area Institute of Science1
- Bioinformatics Resource Center1
- David H. Koch Institute for Integrative Cancer Research1
- Department of Pharmacology and Cecil H. and Ida Green Center for Reproductive Biology Sciences1
- Howard Hughes Medical Institute1
- Laboratory of Molecular Neuro-oncology1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.